Amyloidosis is characterized by remarkable deposition of homogenous insoluble material, amyloid, in the intra- or extra-cellular space of various tissues or organs. Amyloid is a generic term, which derives from certain diverse, approximately 20, sequentially unrelated proteins. This substance is little produced in normal individual, and characterized by showing a peculiar conformational change, named as the cross-β-sheet structure. Protein chains, newly synthesized from ribosome must be folded to compact three-dimensional structures in endoplasmic reticulum(ER), if they may be functionally active. As the protein folding, however, is not always done correctly, such proteins must be degraded or scavenged by ubiquitin-proteasome pathways and/or molecular chaperone systems, because they are prone to aggregate in the tissue.. The neurodegenerative disorders, such as Alzheimer's disease, are directly associated with the aggregation of abnormal protein. The aggregates in such disorders all exhibit, more or less, certain characteristics to be identical to amyloid, which is recently proposed to emerge through the process of protein degradation by proteasomes. In the field of dermatology, a familiar type of primary localized cutaneous amyloidosis(FPLCA) seems to be the most suitable research targets for understanding amyloidgenesis. In this paper, I reviewed the histogenesis of amyloid in FPLCA under the novel concept of protein folding and misfolding, and discussed on the possibility of functional failures of ubiquitin-proteosome pathways and/or molecular chaperone systems, and finally prospected how we can prevent the merging of this substance in comparison with that in Alzheimer's disease. (Online only)
View full abstract